161 related articles for article (PubMed ID: 8899851)
21. Pravastatin transport across the hepatocyte canalicular membrane requires both ATP and a transmembrane pH gradient.
Adachi Y; Okuyama Y; Miya H; Matsusita H; Kitano M; Kamisako T; Yamamoto T
J Gastroenterol Hepatol; 1996 Jun; 11(6):580-5. PubMed ID: 8792314
[TBL] [Abstract][Full Text] [Related]
22. The pharmacokinetics of pravastatin in patients on chronic hemodialysis.
Gehr TW; Sica DA; Slugg PH; Hammett JL; Raymond R; Ford NF
Eur J Clin Pharmacol; 1997; 53(2):117-21. PubMed ID: 9403282
[TBL] [Abstract][Full Text] [Related]
23. Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats.
Kivistö KT; Grisk O; Hofmann U; Meissner K; Möritz KU; Ritter C; Arnold KA; Lutjöohann D; von Bergmann K; Klöting I; Eichelbaum M; Kroemer HK
Drug Metab Dispos; 2005 Nov; 33(11):1593-6. PubMed ID: 16107564
[TBL] [Abstract][Full Text] [Related]
24. Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution.
Li F; Xu D; Shu N; Zhong Z; Zhang M; Liu C; Ling Z; Liu L; Liu X
Xenobiotica; 2015; 45(9):794-802. PubMed ID: 25915109
[TBL] [Abstract][Full Text] [Related]
25. Characterization of Long-Lasting Oatp Inhibition by Typical Inhibitor Cyclosporine A and In Vitro-In Vivo Discrepancy in Its Drug Interaction Potential in Rats.
Taguchi T; Masuo Y; Kogi T; Nakamichi N; Kato Y
J Pharm Sci; 2016 Jul; 105(7):2231-9. PubMed ID: 27290622
[TBL] [Abstract][Full Text] [Related]
26. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
27. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin.
Nezasa K; Higaki K; Takeuchi M; Nakano M; Koike M
Xenobiotica; 2003 Apr; 33(4):379-88. PubMed ID: 12745873
[TBL] [Abstract][Full Text] [Related]
28. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
29. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats.
Shitara Y; Hirano M; Adachi Y; Itoh T; Sato H; Sugiyama Y
Drug Metab Dispos; 2004 Dec; 32(12):1468-75. PubMed ID: 15550721
[TBL] [Abstract][Full Text] [Related]
31. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
32. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Kivistö KT; Niemi M
Pharm Res; 2007 Feb; 24(2):239-47. PubMed ID: 17177112
[TBL] [Abstract][Full Text] [Related]
33. [Kinetic analysis of hepatobiliary transport of drugs: importance of carrier-mediated transport].
Yamazaki M; Nishigaki R; Suzuki H; Sugiyama Y
Yakugaku Zasshi; 1995 Dec; 115(12):953-77. PubMed ID: 8587036
[TBL] [Abstract][Full Text] [Related]
34. Effects of pravastatin and bezafibrate on biliary lipid excretion and hepatic expression of Abcg5 and Abcg8 in the rat.
Kamisako T; Ogawa H
J Gastroenterol Hepatol; 2004 Aug; 19(8):879-83. PubMed ID: 15242490
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.
Yoshikado T; Yoshida K; Kotani N; Nakada T; Asaumi R; Toshimoto K; Maeda K; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2016 Nov; 100(5):513-523. PubMed ID: 27170342
[TBL] [Abstract][Full Text] [Related]
36. Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.
Tsujimoto M; Hatozaki D; Shima D; Yokota H; Furukubo T; Izumi S; Yamakawa T; Minegaki T; Nishiguchi K
Ther Apher Dial; 2012 Dec; 16(6):580-7. PubMed ID: 23190519
[TBL] [Abstract][Full Text] [Related]
37. Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights.
Poulin P; Haddad S
J Pharm Sci; 2018 Jul; 107(7):1791-1797. PubMed ID: 29567347
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver.
Carrella M; Fong LG; Loguercio C; Del Piano C
Metabolism; 1999 May; 48(5):618-26. PubMed ID: 10337863
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
Del Puppo M; Rauli S; Galli Kienle M
Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
[TBL] [Abstract][Full Text] [Related]
40. Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes.
Kwon Y; Morris ME
Pharm Res; 1997 Jun; 14(6):774-9. PubMed ID: 9210196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
